BR112016007627A2 - composições farmacêuticas tópicas para a pele contendo icotinib e utilizações das mesmas - Google Patents
composições farmacêuticas tópicas para a pele contendo icotinib e utilizações das mesmasInfo
- Publication number
- BR112016007627A2 BR112016007627A2 BR112016007627A BR112016007627A BR112016007627A2 BR 112016007627 A2 BR112016007627 A2 BR 112016007627A2 BR 112016007627 A BR112016007627 A BR 112016007627A BR 112016007627 A BR112016007627 A BR 112016007627A BR 112016007627 A2 BR112016007627 A2 BR 112016007627A2
- Authority
- BR
- Brazil
- Prior art keywords
- topical
- preparations
- icotinib
- pharmaceutical compositions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
a presente invenção refere-se a preparações tópicas para inibição de tirosina quinase e métodos de preparação das mesmas, e especialmente a composições farmacêuticas tópicas para inibição de tirosina quinase e métodos de preparação das mesmas. o ingrediente ativo das preparações tópicas é icotinib ou um sal farmaceuticamente aceitável do mesmo. as preparações são adequadas para aplicação tópica, com mínima irritação da pele, sem reações adversas tais como prurido, sensações de queimação, formigamento, pele seca, eritema e rashes, sem efeitos colaterais relacionados com parahormônios tais como atrofia da pele, pigmentação ou hipopigmentação para utilização por longo prazo, bem como sem sintomas dermatológicos relacionados depois de retirada do fármaco. os métodos de preparação são facilmente entendidos, operáveis, e controláveis, e são adequados para produção industrial em massa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013085042 | 2013-10-11 | ||
PCT/CN2014/088344 WO2015051763A1 (zh) | 2013-10-11 | 2014-10-11 | 一种含埃克替尼的皮肤外用药物组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016007627A2 true BR112016007627A2 (pt) | 2017-08-01 |
Family
ID=52812537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016007627A BR112016007627A2 (pt) | 2013-10-11 | 2014-10-11 | composições farmacêuticas tópicas para a pele contendo icotinib e utilizações das mesmas |
Country Status (13)
Country | Link |
---|---|
US (2) | US20160235757A1 (pt) |
EP (1) | EP3056206A4 (pt) |
JP (1) | JP6463745B2 (pt) |
AU (1) | AU2014334222B2 (pt) |
BR (1) | BR112016007627A2 (pt) |
CA (1) | CA2926874C (pt) |
HK (1) | HK1213813A1 (pt) |
IL (1) | IL245015A0 (pt) |
NZ (1) | NZ718802A (pt) |
RU (1) | RU2698796C2 (pt) |
SG (1) | SG11201602826VA (pt) |
TW (1) | TWI630921B (pt) |
WO (1) | WO2015051763A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6523259B2 (ja) * | 2013-06-09 | 2019-05-29 | ベータ ファーマシューティカルズ カンパニー リミテッド | イコチニブリン酸塩の新規な多形及びその使用 |
WO2022022434A1 (zh) * | 2020-07-27 | 2022-02-03 | 杭州和正医药有限公司 | 含托法替尼药学上可接受的盐的药物组合物、制剂及应用 |
WO2022166794A1 (zh) * | 2021-02-02 | 2022-08-11 | 贝达药业股份有限公司 | 埃克替尼在非小细胞肺癌术后辅助治疗中的应用 |
CN116492293A (zh) * | 2022-01-25 | 2023-07-28 | 杭州和正医药有限公司 | 一种含托法替尼的局部用药的药物组合物、制剂及应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2630696A1 (en) * | 2005-11-24 | 2007-05-31 | Basf Se | Keratin-binding effector molecules and method for the production thereof by coupling keratin-binding polypeptides with effector molecules that support carboxylic groups or sulfonic acid groups |
FR2909284B1 (fr) * | 2006-11-30 | 2012-09-21 | Galderma Sa | Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien |
US8822482B2 (en) | 2008-07-08 | 2014-09-02 | Beta Pharma, Inc. | Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof |
GB201010954D0 (en) * | 2010-06-29 | 2010-08-11 | Edko Pazarlama Tanitim Ticaret | Compositions |
WO2012053007A1 (en) * | 2010-10-21 | 2012-04-26 | Cadila Healthcare Limited | Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis |
-
2014
- 2014-10-11 CA CA2926874A patent/CA2926874C/en not_active Expired - Fee Related
- 2014-10-11 JP JP2016521612A patent/JP6463745B2/ja not_active Expired - Fee Related
- 2014-10-11 EP EP14851908.5A patent/EP3056206A4/en not_active Withdrawn
- 2014-10-11 AU AU2014334222A patent/AU2014334222B2/en not_active Ceased
- 2014-10-11 WO PCT/CN2014/088344 patent/WO2015051763A1/zh active Application Filing
- 2014-10-11 RU RU2016118063A patent/RU2698796C2/ru not_active IP Right Cessation
- 2014-10-11 BR BR112016007627A patent/BR112016007627A2/pt not_active IP Right Cessation
- 2014-10-11 NZ NZ718802A patent/NZ718802A/en not_active IP Right Cessation
- 2014-10-11 US US15/028,118 patent/US20160235757A1/en not_active Abandoned
- 2014-10-11 SG SG11201602826VA patent/SG11201602826VA/en unknown
- 2014-10-13 TW TW103135438A patent/TWI630921B/zh not_active IP Right Cessation
-
2016
- 2016-02-22 HK HK16101922.3A patent/HK1213813A1/zh unknown
- 2016-04-10 IL IL245015A patent/IL245015A0/en unknown
-
2019
- 2019-04-30 US US16/398,827 patent/US20190321369A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2698796C2 (ru) | 2019-08-30 |
RU2016118063A (ru) | 2017-11-16 |
WO2015051763A1 (zh) | 2015-04-16 |
CA2926874C (en) | 2018-12-11 |
EP3056206A4 (en) | 2017-07-05 |
AU2014334222B2 (en) | 2017-03-09 |
US20190321369A1 (en) | 2019-10-24 |
TWI630921B (zh) | 2018-08-01 |
HK1213813A1 (zh) | 2016-07-15 |
CA2926874A1 (en) | 2015-04-16 |
IL245015A0 (en) | 2016-05-31 |
AU2014334222A1 (en) | 2016-05-05 |
TW201513894A (zh) | 2015-04-16 |
EP3056206A1 (en) | 2016-08-17 |
JP2016532659A (ja) | 2016-10-20 |
NZ718802A (en) | 2017-09-29 |
SG11201602826VA (en) | 2016-05-30 |
US20160235757A1 (en) | 2016-08-18 |
JP6463745B2 (ja) | 2019-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL264413B (en) | Preparations containing fibers obtained electrohydrodynamically for delivering specific doses of active substance to the skin or mucous membrane | |
SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
BR112016000561B8 (pt) | Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma | |
TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
PH12016500978A1 (en) | Piperazine derivatives having multimodal activity against pain | |
MY167691A (en) | A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid | |
MX2015010185A (es) | Composicion para uso cosmetico adecuada para producir un efecto de pigmentacion sobre el cabello. | |
BR112016021023A8 (pt) | composições de corticosteroides tópicos | |
MX2016006604A (es) | Derivados de piperidina con actividad multimodal contra el dolor. | |
MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
BR112016007627A2 (pt) | composições farmacêuticas tópicas para a pele contendo icotinib e utilizações das mesmas | |
ECSP14010868A (es) | Fenilimidazopirazoles sustituidos y su uso | |
HK1222337A1 (zh) | 用於施加藥物活性成分或化妝品活性成分的局部組合物和載體 | |
MX2018000262A (es) | Usos terapeuticos de formulaciones de berberina. | |
CO2018011797A2 (es) | Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor | |
TR201908151T4 (tr) | İzoindolin türevleri. | |
BR112016017496A2 (pt) | Composição para acelerar a penetração através da pele, preparação para administração transdérmica e preparação de emplastro de pele | |
MX2015014905A (es) | Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos. | |
CO2018004803A2 (es) | Compuestos oxa-diazaspiro que tienen actividad contra el dolor | |
MX2018004774A (es) | Derivados de morfolina sustituidos que tienen actividad contra el dolor. | |
PH12015502420A1 (en) | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | |
BR112014032850A2 (pt) | combinações de princípios ativos, preparações cosméticas ou dermatológicas, e, uso de combinações de princípios ativos | |
MX2012006272A (es) | Uso de la betanidina, isobetanidina y sus derivados para preparar un medicamento para el tratamiento de ateroscleosis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |